Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$191.56 USD

191.56
274,310

-2.75 (-1.42%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $191.61 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced

Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.

Here's Why Investors Should Retain Phibro (PAHC) for Now

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing

The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.

Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection

The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.

ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs

ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.

CVS Health (CVS) Invests in Renewable Energy With New Pact

CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).

Encompass Health's (EHC) 158th Hospital Opens in Maryland

The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.

Charles River's (CRL) Improved Volume Aids Amid Margin Woe

Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.

Here's Why You Should Retain Alcon (ALC) Stock for Now

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.

Charles River (CRL) Introduces LVV Packaging Plasmids

Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer

Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.

Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform

Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.

Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers

Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI

The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.

Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger

Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.

Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture

Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) backed by the continued demand for digital health solutions.

UnitedHealth Group (UNH) Hikes Quarterly Dividend by 14%

UnitedHealth Group's (UNH) recent dividend hike highlights a solid financial position and efforts to sustain its sound capital deployment history.

Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan

Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.

Zacks.com featured highlights include Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop

Penumbra, Lamb Weston Holdings, Transportadora de Gas del Sur and Vipshop are part of the Zacks Screen of the Week article.

Syneos Health (SYNH) Sell-Off Appears Strategic Amid Margin Woes

Syneos Health's (SYNH) purchase price represents a 24% premium to its unaffected closing stock price prior to the announcement. Margin pressure continues to weigh on the stock.